February 7, 2020 / 8:44 AM / 18 days ago

BRIEF-Synact To Report About Phase IIA Of AP1189 In Q2 2020, Not Q1

Feb 7 (Reuters) - SynAct Pharma AB:

* WILL REPORT INTERIM DATA FROM ONGOING PHASE IIA STUDY OF AP1189 IN PATIENTS WITH RHEUMATOID ARTHRITIS IN Q2 2020, NOT IN Q1 2020 AS PREVIOUSLY EXPECTED

* REPORTING OF TOPLINE RESULT STILL EXPECTED DURING Q1 2021 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below